Forbes: U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment

Summary: Forbes reports on Massachusetts-based startup Delix Therapeutics’ decision to work with the National Institute on Drug Abuse (NIDA) to test its patented version of ibogaine as a potential treatment for substance-use disorders.

Originally appearing here (Archived)